Olema Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
OLMA$7.36+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
(Amounts in thousands, except for share amounts)
| Accumulated | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||||
| Shares · Amount · Capital · Income · Deficit · Equity | |||||||||||
| Balances at December 31, 2023 | 54,992,784 | $ | 5 | $ | 559,175 | $ | 347 | $ | (305,632) | $ | 253,895 |
| Issuance of shares and pre-funded warrants under 2024 private placement, net of issuance costs of $12,998 | 19,928,875 | 2 | 236,999 | — | — | 237,001 | |||||
| Issuance of shares under at-the-market offering, net of issuance costs of $166 | 1,772,278 | — | 22,787 | — | — | 22,787 | |||||
| Exchange of common stock shares for pre-funded warrants | (3,420,000) | — | — | — | — | — | |||||
| Stock-based compensation expense | — | — | 22,009 | — | — | 22,009 | |||||
| Exercise of stock options | 430,159 | — | 1,518 | — | — | 1,518 | |||||
| Issuance of shares under employee stock purchase plan | 112,853 | — | 859 | — | — | 859 | |||||
| Employee stock purchase plan expense | — | — | 573 | — | — | 573 | |||||
| Vesting of performance-based restricted stock unit awards | 403,000 | — | — | — | — | — | |||||
| Vesting of restricted stock awards | 92,659 | — | — | — | — | — | |||||
| Net unrealized loss on marketable securities | — | — | — | (204) | — | (204) | |||||
| Net loss | — | — | — | — | (129,474) | (129,474) | |||||
| Balances at December 31, 2024 | 74,312,608 | $ | 7 | $ | 843,920 | $ | 143 | (435,106) | $ | 408,964 | |
| Issuance of shares upon follow-on public offering, net of issuance costs of $13,688 | 11,500,000 | 1 | 204,797 | — | — | 204,798 | |||||
| Exchange of common stock shares for pre-funded warrants | (6,070,000) | — | — | — | — | — | |||||
| Stock-based compensation expense, including employee stock purchase plan expense | — | — | 17,586 | — | — | 17,586 | |||||
| Exercise of stock options | 1,351,320 | — | 8,154 | — | — | 8,154 | |||||
| Issuance of shares under employee stock purchase plan | 282,521 | — | 1,030 | — | — | 1,030 | |||||
| Net unrealized gain on marketable securities | — | — | — | 478 | — | 478 | |||||
| Net loss | — | — | — | — | (162,451) | (162,451) | |||||
| Balances at December 31, 2025 | 81,376,449 | $ | 8 | $ | 1,075,487 | $ | 621 | (597,557) | $ | 478,559 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.